Lumos Pharma: LUM-201 In PGHD Offers Significant Upside Potential [Seeking Alpha]
Ascendis Pharma A/S - Ordinary Share (ASND)
Last ascendis pharma a/s - ordinary share earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Seeking Alpha
SummaryLumos Pharma, Inc. is a clinical-stage biopharmaceutical company that currently trades around a 50% discount to pro forma cash.The company is developing LUM-201 (oral ibutamoren) in pediatric growth hormone deficiency (PGHD), for which current treatment options are limited to injectables.Given the commercial opportunity for the drug, it's possible the company could trade near a $300-400 million market cap by Phase 2 readout.Sufficient safety and proof-of-concept data already exist to support LUM-201's development and eventual commercialization in PGHD.The commercial opportunity is significant: given the choice between an injectable medication and an oral for their child, parents will choose an oral every time.Overview of Lumos PharmaLumos Pharma, Inc. (NASDAQ:LUMOmergerAs of March 31, 2020, the company's pro formacash position$6.5-7.5 millionLead Asset LUM-201 in PGHDPediatric growth hormone deficiencyLumos's lead product candidate LUM-201 is an oral growth hormone stimulating
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - Ordinary Share news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028GlobeNewswire
- Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqGlobeNewswire
- Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.MarketBeat
- Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.MarketBeat
- Ascendis Pharma to List Ordinary Shares Directly on NasdaqGlobeNewswire
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 4/21/26 - Form 6-K
- 4/21/26 - Form 6-K
- 4/20/26 - Form 8-A12B/A
- ASND's page on the SEC website